Pricing pressure continues to remain a key headwind for the growth of pharma companies in the US market
Listen to this article
NEW DELHI : The June quarter results of the four large pharma companies recently have shown the impact of rising costs on profitability. Domestic growth also remained subdued on a large base of last year that had seen greater contribution of covid treatment drugs. The competitive intensity in the US market remains high as was evident from Dr Reddy’s Laboratories and Lupin’s North America sales, which fell 11% and 28.7% sequentially respectively, pulling down overall earnings growth. Sun Pharmaceutical and Cipla nevertheless managed to report growth as their product portfolio of niche products helped take care of competitive intensity in the US.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.